Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

61. The Diagnostic Value of a Digital Rectal Examination Compared With High-Resolution Anorectal Manometry in Patients With Chronic Constipation and Fecal Incontinence (Abstract)

The Diagnostic Value of a Digital Rectal Examination Compared With High-Resolution Anorectal Manometry in Patients With Chronic Constipation and Fecal Incontinence Digital rectal examination (DRE) is a simple clinical method to diagnose anorectal disorders. High-resolution antorectal manometry (HRAM) based on a spatiotemporal plot is expected to promote improved diagnostic accuracy. However, there are no reports comparing the effectiveness of DRE and HRAM. The aim of our study was therefore (...) to evaluate the diagnostic value of DRE compared with HRAM.A total of 309 consecutive patients with chronic constipation (n=268) or fecal incontinence (n=41) who underwent a standardized DRE, HRAM, and balloon expulsion test were enrolled in this study. The diagnostic yield of DRE compared with HRAM was determined, and agreement between DRE and HRAM data was evaluated.Of the constipated patients, 207 (77.2%) were diagnosed with dyssynergia using HRAM. The sensitivity, specificity, and positive predictive

2015 EvidenceUpdates

62. Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association

Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association: Clinical Effectiveness and Cost-Effectiveness DATE: 07 July 2015 RESEARCH QUESTIONS 1. What is the clinical effectiveness of the Peristeen anal irrigation system for the management of incontinence and constipation in patients with VACTERL association? 2. What is the cost-effectiveness of the Peristeen anal irrigation system for the management of incontinence and constipation in patients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

63. Laxatives for the management of constipation in people receiving palliative care. Full Text available with Trip Pro

Laxatives for the management of constipation in people receiving palliative care. This article describes the second update of a Cochrane review on the effectiveness of laxatives for the management of constipation in people receiving palliative care. Previous versions were published in 2006 and 2010 where we also evaluated trials of methylnaltrexone; these trials have been removed as they are included in another review in press. In these earlier versions, we drew no conclusions on individual (...) effectiveness of different laxatives because of the limited number of evaluations. This is despite constipation being common in palliative care, generating considerable suffering due to the unpleasant physical symptoms and the availability of a wide range of laxatives with known differences in effect in other populations.To determine the effectiveness and differential efficacy of laxatives used to manage constipation in people receiving palliative care.We searched the Cochrane Central Register of Controlled

2015 Cochrane

64. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation Full Text available with Trip Pro

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation Prucalopride is effective at alleviating symptoms of chronic constipation in women. The aim of this study was to assess the efficacy of 12 weeks of prucalopride treatment compared with placebo in men with chronic constipation.This was a multicenter, stratified, randomized, parallel-group, double-blind, placebo-controlled, phase 3 study (...) (ClinicalTrials.gov identifier: NCT01147926). The primary end point was the proportion of patients with a mean of three or more spontaneous complete bowel movements (SCBMs) per week across the treatment period. Efficacy end points were assessed using daily electronic diaries, global assessment of the severity of constipation and efficacy of treatment, and Patient Assessment of Constipation-Symptoms (PAC-SYM) and Patient Assessment of Constipation-Quality of Life (PAC-QOL) questionnaires.In total, 374 patients

2015 EvidenceUpdates Controlled trial quality: predicted high

65. Constipation. (Abstract)

Constipation. This issue provides a clinical overview of constipation, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration with the ACP's Medical

2015 Annals of Internal Medicine

66. Enemas for the Treatment of Constipation in the Emergency Department

Enemas for the Treatment of Constipation in the Emergency Department Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Enemas for the Treatment of Constipation

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

67. Colonoscopy in Patients with Constipation

Colonoscopy in Patients with Constipation Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Colonoscopy in Patients with Constipation: Clinical Effectiveness and Guidelines DATE

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

68. Systematic review and meta-analysis: Poor quality evidence to support the use of biofeedback for the treatment of functional constipation in adults

Systematic review and meta-analysis: Poor quality evidence to support the use of biofeedback for the treatment of functional constipation in adults Poor quality evidence to support the use of biofeedback for the treatment of functional constipation in adults | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Poor quality evidence to support the use of biofeedback for the treatment of functional constipation in adults Article Text Primary

2015 Evidence-Based Nursing

69. Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation Full Text available with Trip Pro

Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Results | Pain Medicine | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Close mobile search navigation Search Results for Consensus (...) Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation Modify your search Querybuilder input Citation Year Citation Volume Citation Issue Number Citation Page Filter Abstract All Authors DOI Full Text Keywords References Title Querybuilder input Citation Year Citation Volume Citation Issue Number Citation Page Filter Abstract All Authors DOI Full Text Keywords References Title Querybuilder input Citation Year Citation Volume Citation Issue Number Citation Page Filter Abstract All

2015 American Academy of Pain Medicine

70. Management of Constipation in Adult Patients Receiving Palliative Care

Management of Constipation in Adult Patients Receiving Palliative Care Management of Constipation in Adult Patients Receiving Palliative Care National Clinical Guideline No. 10 November 2015Guideline Development Group The Management of Constipation in Adult Patients Receiving Palliative Care Guideline was developed by a subgroup of the Health Service Executive (HSE)/Royal College of Physicians of Ireland (RCPI) National Clinical Programme for Palliative Care, known as the Guideline Development (...) advice should be sought. This guideline may also be of interest to patients with a life-limiting condition and their carers. This guideline should not be used in patients without a life-limiting illness. This guideline does not apply to children. The National Clinical Guideline and the summary National Clinical Guideline are available on the websites www.health.gov.ie/patient-safety/NCEC and www.hse.ie/palliativecareprogramme. Constipation is one of the most frequently encountered symptoms

2015 National Clinical Guidelines (Ireland)

71. Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement

Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement - Maeda - 2015 - Colorectal Disease - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term Consensus Statement Free Access Sacral nerve stimulation for faecal incontinence and constipation: a European (...) not encountered in the early assessments have been reported - and their management has largely been based on trial and error. There have been many studies on the initial selection criteria for SNS for FI, such as excluding patients with a sphincter defect. The sensitivity of the currently existing assessment procedure, such as the period of peripheral nerve evaluation (PNE), incontinence scores and bowel diaries, has been questioned. There is little information on the long‐term outcome of SNS for constipation

2015 Palliative Care Evidence Review Service (PaCERS)

72. Treatments for Constipation

Treatments for Constipation TITLE: Treatments for Constipation: A Review of Systematic Reviews DATE: 17 November 2014 CONTEXT AND POLICY ISSUES Constipation has many definitions and is often described differently depending on the population queried. Physicians may define constipation as a reduction in the frequency of bowel movements to fewer than three times per week while patients identify more with the symptoms associated with constipation such as difficulty passing stool, hard stool (...) consistency, feelings of abdominal cramping, and feelings of incomplete stool passage. 1 Causes of constipation may be primary (idiopathic) or secondary to other factors such as diet, medication, or medical conditions. 2 Constipation can affect anyone as a minor annoyance but up to a quarter of the population experiences it chronically or severely. 2 It can substantially affect quality of life and be debilitating. 2 It is estimated that between 2% to 27% of the population are affected depending upon

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

73. Prucalopride (Resolor) for adult males with chronic constipation ? third line

Prucalopride (Resolor) for adult males with chronic constipation ? third line Prucalopride (Resolor) for adult males with chronic constipation – third line Prucalopride (Resolor) for adult males with chronic constipation – third line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Prucalopride (Resolor) for adult males (...) with chronic constipation – third line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adult; Benzofurans; Chronic Disease; Constipation; Laxatives; Male Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public

2014 Health Technology Assessment (HTA) Database.

74. Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain

Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Opioid; Constipations; Naltrexone; Narcotic Antagonists Language Published English Country of organisation England English summary

2014 Health Technology Assessment (HTA) Database.

75. Interventions for treating postpartum constipation. Full Text available with Trip Pro

Interventions for treating postpartum constipation. Constipation is a functional bowel disorder that can reduce quality of life in the puerperium period. The diagnosis of postpartum constipation is both subjective and objective. It is characterised by symptoms such as pain or discomfort, straining, hard lumpy stools and a sense of incomplete bowel evacuation. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones and hematinics used in pregnancy can increase the risk (...) of postpartum constipation. Although a high fibre diet and increased fluid intake is encouraged to assist defecation in the puerperium, pain-relieving drugs and laxatives are common drugs of choice to alleviate constipation. However, the effectiveness and safety of laxatives on the nursing mother need to be ascertained.To evaluate the effectiveness of interventions for treating postpartum constipation.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (28 March 2014), the metaRegister

2014 Cochrane

76. Lubiprostone for treating chronic idiopathic constipation

Lubiprostone for treating chronic idiopathic constipation Lubiprostone for treating chronic idiopathic constipation | Guidance | NICE Lubiprostone for treating chronic idiopathic constipation Technology appraisal guidance [TA318] Published date: 23 July 2014 Guidance This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza). Explore © NICE [year]. All rights reserved. Subject to .

2014 National Institute for Health and Clinical Excellence - Technology Appraisals

77. Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation

Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation TITLE: Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation: A Review of the Clinical Effectiveness DATE: 26 June 2014 CONTEXT AND POLICY ISSUES Constipation has many definitions and is often described differently depending on the population queried. Many physicians define constipation as a reduction in the frequency of bowel movements (...) to fewer than three times per week while patients identify more with the symptoms associated with constipation such as difficulty passing stool, hard stool consistency, feelings of abdominal cramping, and feelings of incomplete stool passage. 1 Causes of constipation may be primary (idiopathic) or secondary to other factors such as diet, medication, or medical conditions. 2 Constipation can affect anyone as a minor annoyance but up to a quarter of the population experiences it chronically or severely

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

78. Docusate for treatment of constipation

Docusate for treatment of constipation Docusate for treatment of constipation Docusate for treatment of constipation Mitchell MD, Williams K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Williams K. Docusate for treatment of constipation. Philadelphia: Center for Evidence-based Practice (CEP). 2014 Final publication URL Indexing Status Subject (...) indexing assigned by CRD MeSH Constipation; Dioctyl Sulfosuccinic Acids Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2@uphs.upenn.edu AccessionNumber 32014000628 Date abstract record published 17/06/2014 Health Technology Assessment (HTA) database Copyright © 2019

2014 Health Technology Assessment (HTA) Database.

79. Biofeedback for treatment of chronic idiopathic constipation in adults. Full Text available with Trip Pro

Biofeedback for treatment of chronic idiopathic constipation in adults. Biofeedback therapy has been used to treat the symptoms of people with chronic constipation referred to specialist services within secondary and tertiary care settings. However, different methods of biofeedback are used within different centres and the magnitude of suggested benefits and comparable effectiveness of different methods of biofeedback has yet to be established.To determine the efficacy and safety of biofeedback (...) for the treatment of chronic idiopathic (functional) constipation in adults.We searched the following databases from inception to 16 December 2013: CENTRAL, the Cochrane Complementary Medicine Field, the Cochrane IBD/FBD Review Group Specialized Register, MEDLINE, EMBASE, CINAHL, British Nursing Index, and PsychINFO. Hand searching of conference proceedings and the reference lists of relevant articles was also undertaken.All randomised trials evaluating biofeedback in adults with chronic idiopathic constipation

2014 Cochrane

80. Movantik (naloxegol) - To treat opioid-induced constipation in adults with chronic non-cancer pain

Movantik (naloxegol) - To treat opioid-induced constipation in adults with chronic non-cancer pain Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - MOVANTIK (naloxegol) Tablets Company: AstraZeneca Pharmaceuticals LP Application No.: 204760 Approval Date: 9/16/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2014 FDA - Drug Approval Package